Ranunculus ternatus THUNB. is a plant belonging to the Ranunculaceae family and is widely distributed in the Henan region of China. The root of R. ternatus is used by traditional practitioners as a treatment for tuberculosis 1) and its ethanol extract has exhibited obviously antituberculosis activities. 2) To investigate the bioactive antituberculosis constituents present, we have undertaken systematic chemical and pharmaceutical research work on this plant. About 20 compounds have been isolated from the roots of R. ternatus, including some fatty acid esters, 5-hydroxymethyl furoic acid and four glycosides. [3] [4] [5] [6] [7] Further research has led to two more new indolopyridoquinazoline alkaloidal glucosides, compound 1 (ternatoside C) and compound 2 (ternatoside D) from this plant, and alkaloidal glycoside compounds are reported for the first time to be obtained from Ranunculus genus. In this paper, we report the isolation and structural elucidation of these two compounds on the basis of spectroscopic and chemical methods.
Results and Discussion
The ethanolic extract of the dried roots was evaporated in vacuo, and then the residue was suspended in H 2 O and the H 2 O soluble part was submitted to D 101 macroporous resin column chromatography. The 75% ethanol elutant from the D 101 macroporous resin column was separated by a combination of silica gel and Sephadex LH-20 column chromatography which led to two new alkaloidal glycoside compounds 1 and 2.
Compound 1 was obtained as a brown powder, mp 185-187°C, and reacted positively to the Dragendorff reagent. The UV spectrum showed l max (MeOH) (log e) at 222 (4.61) and 353 (4.86) nm, which suggested the existence of a conjugated structure (alkaloid aglycone) in compound 1, and the absorption of IR spectrum at 1690 cm Ϫ1 showed the existence of a conjugated carbonyl group. C-NMR data of 11-hydroxyrutaecarpine, the chemical shift of C-11 had shifted downfield for 27.8 ppm while the chemical shifts of C-10 and C-12 had shifted upfield for 6.3 and 6.9 ppm, respectively, which suggested that C-11 of 1 should be glycosylated. The HMBC correlation achieved between the anomeric proton at d H 4.78 (H-1Ј) and C-11(d C 151.9) also supported a C-11 location for the sugar unit.
Thus, the structure of compound 1 was established as 11-O-b-D-glucopyranosyl rutaecarpine, and it was named ternatoside C (Fig. 1) .
Compound 2 was obtained as a brown powder, mp 172-175°C, and also gave a positive result to Dragendorff's reagent. Its molecular formula was determined to be The UV spectrum of compound 2 showed l max (MeOH) (log e) at 220 (4.51) and 351 (4.88) nm, gave the same conjugated alkaloid aglycone as that of compound 1. IR spectrum of 2 also displayed an absorption band of a conjugated carbonyl group at 1690 cm Ϫ1 . The NMR data of 2 resembled those of 1 except 2 had one more pentose unit than compound 1 (Table 1) . These two sugar units were proved to be a D-glucose and an L-rhamnose respectively by comparing their 13 C-NMR data with those reported in the literature, 10, 12) and were confirmed by GC analysis after the acid hydrolysis and preparation of their thiazolidine derivatives.
11 Therefore, the structure of 2 was elucidated as 11-O-a-L-rhamnosyl-(1→6)-b -D-glucopyranosyl rutaecarpine, and named ternatoside D (Fig. 2) .
Assignment of all the NMR signals of compound 2 was achieved through a combination of (Table 1) .
Rutaecarpine is a main quinazolinocarboline alkaloid isolated from Evodia rutaecapa, a famous traditional Chinese medicine, and shows a variety of pharmacological effects including antithrombotic and vasorelaxant effects. 13) Ueng et al. reported recently that 11-hydroxyrutaecarpine was one of the oxidation metabolites of rutaecarpine by liver microsomal enzymes in rats. 8) In general, xenobiotic hydroxylation metabolites have higher hydrophilicity than their parent compounds and show less biological activities or toxicities. It is clear that compounds 1 and 2 with more glycosyl than 11-hydroxyrutaecarpine showed higher hydrophilicity. Thus, further studies on the pharmacological and toxicological effects of compounds 1 and 2 are needed before clinical application.
Experimental
General Melting points were measured on a Fisher-Johns apparatus and were uncorrected. IR spectra were recorded on a Perkin-Elmer 983G spectrometer. One-and two-dimensional NMR spectra were recorded on a Bruker 500 spectrometer. The ESI-MS and HR-ESI-MS were recorded in a LCQ DECA XP plus spectrometer. GC-MS was performed using a SHI-MADZU QP5050A. 1 and 2 (each 5 mg) were dissolved in water (100 ml) and 2 M HCl (100 ml) and then heated at 100°C for 1 h. The mixture was then passed through an Amberlite IRA-60E column (6ϫ50 mm) and the eluate was concentrated. The residue was dissolved in pyridine (25 ml) and stirred with D-cysteine methyl ester (4.0 mg) for 1.5 h at 60°C. To the reaction mixture, hexamethyldisilazan (10 ml) and trimethylsilyl chloride (10 ml) were added and the mixture was stirred for 30 min at 60°C. The supernatant was then analyzed by GC [Column: DB-50, 25 mmϫ30 m; column temperature: 235°C; carrier gas: N 2 ; retention time: D-Glc (16.5 min), L-Glc (16.1 min), D-Rha (13.2 min), L-Rha (12.9 min). D-Glucose and Lrhamnose were detected from the new compound.
